Asthma biomarkers in children. new opportunities, real practice and frontiers

Author:

Pampura N.1ORCID,Kamaev A. V.2ORCID,Lebedenko A. A.3ORCID

Affiliation:

1. Veltischev Research and Clinical Institute for Pediatrics, Pirogov Russian National Research Medical University; Russian Medical Academy of Continuous Professional Education; Morozov Children’s Municipal Clinical Hospital

2. Pavlov First Saint-Petersburg State Medical University

3. Rostov State Medical University

Abstract

Personalized management of children with chronic inflammatory non-communicable diseases, including bronchial asthma, have been extremely elaborated last decade. Highly informative biomarkers exploring is one of important conditions of this management. Testing aim, molecule’s pathogeneticrole, adequate biomaterial choice and test validity determine possibility and effectiveness of biomarker application. The paper represents key features of most perspective asthma biomarkers and discuss advantages and disadvantages of their using in pediatric practice. with rational biomarkers implementation nowadays one can separate patients with asthma development risk, provide a rational prevention, confirm the diagnosis and evaluate severity in some cases, optimize anti-inflammatory treatment, prognose the treatment response, evaluate future exacerbation probability, devote children with severe asthma in-time to initiate and conduct biological therapy for them.

Publisher

Rostov State Medical University

Subject

General Earth and Planetary Sciences,General Environmental Science

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3